Campbell D J, Bouhnik J, Coezy E, Menard J, Corvol P
Mol Cell Endocrinol. 1985 Nov;43(1):31-40. doi: 10.1016/0303-7207(85)90039-5.
We have studied the processing of rat and human angiotensinogen precursors by microsomal membranes as a means of determining the number of asparagine-linked oligosaccharide units per angiotensinogen molecule, and thus the utilization of potential sites of N-glycosylation. Glycosylated, processed forms of angiotensinogen were isolated by chromatography on lentil lectin-Sepharose 4B. 35S-Methionine-labeled precursor and processed forms of angiotensinogen were compared with glycosylated and nonglycosylated 35S-methionine-labeled mature forms of angiotensinogen secreted by hepatoma cells, using immunoprecipitation, sodium dodecyl sulfate-polyacrylamide gel electrophoresis and autoradiography. N-Glycosylation of secreted angiotensinogen was inhibited using tunicamycin. For rat angiotensinogen, only 2 of 3 potential sites of N-glycosylation were utilized; in contrast, all 4 potential sites of N-glycosylation of human angiotensinogen were utilized. For neither rat or human angiotensinogen precursor was there any evidence for a prosequence.
我们研究了微粒体膜对大鼠和人血管紧张素原前体的加工过程,以此来确定每个血管紧张素原分子上天冬酰胺连接的寡糖单位数量,进而确定N-糖基化潜在位点的利用情况。通过扁豆凝集素-琼脂糖4B柱层析法分离糖基化的、加工后的血管紧张素原形式。利用免疫沉淀、十二烷基硫酸钠-聚丙烯酰胺凝胶电泳和放射自显影技术,将35S-甲硫氨酸标记的血管紧张素原前体及加工后的形式,与肝癌细胞分泌的糖基化和非糖基化的35S-甲硫氨酸标记的血管紧张素原成熟形式进行比较。使用衣霉素抑制分泌型血管紧张素原的N-糖基化。对于大鼠血管紧张素原,3个潜在的N-糖基化位点中只有2个被利用;相比之下,人血管紧张素原的所有4个潜在N-糖基化位点都被利用了。无论是大鼠还是人血管紧张素原前体,均未发现有前导序列的证据。